Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation

摘要: There is currently no consensus on the most suitable treatment for recurrence of hepatocellular carcinoma (HCC) after liver transplantation. This open, multicenter, retrospective, uncontrolled cohort study was designed to evaluate safety and preliminary efficacy combined use a mammalian target rapamycin (mTOR) inhibitor sorafenib in this setting. In 31 patients who suffered from HCC transplantation, immunosuppressive therapy changed mTOR inhibitors, systemic with initiated. combination maintained until symptomatic tumor progression, death, hepatic decompensation, or unacceptable toxicity occurred. Primary determined by overall survival progression-free survival, secondary response rate. Toxicity parameters associated inhibitors were also analyzed. The rate according Response Evaluation Criteria Solid Tumors 3.8% (1/26), there sustained stabilization disease 13 additional cases (50.0%). median 19.3 months [95% confidence interval (CI) = 13.4–25.1 months], time progression 6.77 (95% CI 2.3–11.1 months). Only 2 grade 3/4 hyperglycemia 1 case mucositis reported, they possibly related inhibitors. common severe adverse event probably diarrhea (12.9%). conclusion, coadministration an could be effective despite notable post–liver transplant not radical therapy. need further evaluated randomized controlled studies considered valid option. Liver Transpl 18:45–52, 2012. © 2011 AASLD.